Amgen is a publicly traded company in the Technology sector. This company operates across Technology and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 5 active Congressional signals mentioning Amgen, including 5 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
Allen Investment Management disclosed a $153.9M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$12.6M position
Adams Asset Advisors
Adams Asset Advisors disclosed a $12.6M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$12.5M position
American National Bank & Trust
American National Bank & Trust disclosed a $12.5M position in Amgen Inc Com ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$8.9M position
Alley Investment Management Company
Alley Investment Management Company disclosed a $8.9M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$8.5M position
Albion Financial Group /ut
Albion Financial Group /ut disclosed a $8.5M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$5.8M position
180 Wealth Advisors
180 Wealth Advisors disclosed a $5.8M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$4.5M position
Alteri Wealth
Alteri Wealth disclosed a $4.5M position in AMGEN INC COM ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$4.5M position
Alkeme Wealth
Alkeme Wealth disclosed a $4.5M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$2.5M position
111 Capital
111 Capital disclosed a $2.5M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
13F + Contract$2.0M position
Atwood & Palmer
Atwood & Palmer disclosed a $2.0M position in AMGEN INC ($AMGN) in its 2026-03-31 13F filing. AMGEN USA INC was separately awarded a $839.9M contract by Department of Health and Human Services.
HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
→ Near-term capex pressure from building or contracting domestic manufacturing capacity; long-term reduction in IP theft risk and supply chain security
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
→ Manufacturers face increased compliance costs for recall infrastructure and higher potential liability from mandatory recalls.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
→ Hospitals must receive separate, pass-through payment at ASP for qualifying cancer drugs, removing the financial disincentive against administering high-cost branded oncology therapies that would otherwise be absorbed into bundled payments.
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
→ Amgen faces procurement compliance costs but can claim 100% bonus depreciation on domestic manufacturing investments.
HR6485 (Skinny Labels, Big Savings Act) creates a statutory safe harbor protecting generic and biosimilar manufacturers from patent infringement liability when marketing drugs for non-patented indications, directly reversing the GlaxoSmithKline v. Teva precedent. Generic makers TEVA and VTRS are structural winners, with reduced litigation risk supporting their generic launch strategies. Brand-name manufacturers AMGN, PFE, JNJ, and MRK face accelerated competitive erosion on their top-selling drugs. The bill is early-stage (referred to House Judiciary), but companion Senate bill S43 signals bipartisan interest.
→ Accelerated market entry of generic and biosimilar competitors for branded drugs' non-patented indications, eroding sales volume and pricing power on those uses. Brand manufacturers lose the ability to use method-of-use patents indirectly to block skinny label competition.